Quetiapine - Schizophrenia and other psychoses
You are here : Home > Formulary Search > Quetiapine - Schizophrenia and other psychoses
Status 1
- Immediate release tablets
Initiation and stabilisation by a SABP specialist for a minimum of 3 months before any request for transfer of prescribing responsibility.
Status 2
- Modified release tablets
Modified release tablets are reserved for use when immediate release tablets are not suitable.
Modified release quetiapine MAY be continued in Primary Care (after a 3-month period of stabilisation by SABP) where the use of immediate release tablets would risk destabilising the patient.
Documentation
PAD Profile
Other Indications
Below are listed other indications that Quetiapine is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Schizophrenia and other psychoses.
Committee Recommendations (1)
Immediate release (IR) quetiapine should be used in preference to the XL formulations as recommended by the PCN in May 2012.
Quetiapine IR should be prescribed generically. The Seroquel brand was assigned a BLACK traffic light status by the PCN in May 2017
SABP have updated (Jan 2018) a number of resources aimed at supporting the use of IR quetiapine in preference to the XL formulations - see below
Where quetiapine is used in Behavioural and Psychological Symptoms of Dementia (BPSD), please see separate entry Quetiapine - Behavioural and Psychological Symptoms of Dementia - surrey.res.services